Search

Your search keyword '"Carr, Edward J"' showing total 231 results
Start Over Author "Carr, Edward J"
231 results on '"Carr, Edward J"'

1. Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study

Author

Russell, Timothy W, Townsley, Hermaleigh, Hellewell, Joel, Gahir, Joshua, Shawe-Taylor, Marianne, Greenwood, David, Hodgson, David, Hobbs, Agnieszka, Dowgier, Giulia, Penn, Rebecca, Sanderson, Theo, Stevenson-Leggett, Phoebe, Bazire, James, Harvey, Ruth, Fowler, Ashley S, Miah, Murad, Smith, Callie, Miranda, Mauro, Bawumia, Philip, Mears, Harriet V, Adams, Lorin, Hatipoglu, Emine, O'Reilly, Nicola, Warchal, Scott, Ambrose, Karen, Strange, Amy, Kelly, Gavin, Kjar, Svend, Papineni, Padmasayee, Corrah, Tumena, Gilson, Richard, Libri, Vincenzo, Kassiotis, George, Gamblin, Steve, Lewis, Nicola S, Williams, Bryan, Swanton, Charles, Gandhi, Sonia, Beale, Rupert, Wu, Mary Y, Bauer, David L V, Carr, Edward J, Wall, Emma C, and Kucharski, Adam J

Published
2025
Full Text
View/download PDF

2. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

Author

Beesley, Richard, Churchill, Vicky, Insch, Elspeth, Loughton, Holly, MacDonald, Eilean, Lax, Siân, Lowe, Faye, Magwaro, Sophia, Gradwell, Mark, Kinsella, Francesca, Rolfe, Hayley, McIntyre, Stacey, Mortimer, Paige, Al-Taei, Saly, Tadros, Susan, Workman, Sarita, Arnott, Maxine, Brock, James, Melville, Andrew, Najm, Aurelie, Rutherford, Matthew, Sunzini, Flavia, Herman, Lou S, Hobbs, Agnieszka, Ragno, Martina, Wu, Mary Y, Selby, Rachael, Clay, Jennifer, Hutchison, Clare, Lown, Robert, Lwin, May N, Meardon, Naomi, Kelleher, Peter, Lightstone, Liz, Walters, Thomas, Denyer, Jayne, Ibrahim, Rahima, Gleeson, Sarah, Martin, Paul, McAdoo, Stephen, Baker, Helena, Horswill, Sarah, Parungao, Nina, Saich, Stephen, Cullinane, James, Irwin, Sophie, Klenerman, Paul, Marjot, Thomas, Chakraverty, Ronjon, Holroyd, Christopher, Kavi, Janki, Trown, Doreen, Babbage, Gavin, Chackathayil, Julia, Faria, Patricia, Ingham, Karen, Miah, Murad, Miranda, Mauro, O'Reilly, Nicola, Smith, Callie, Driver, Kimberley, Gauntlett, Kaylee, Farthing, Andrew, Rundell, Suzann, Smith, Emily, Tong, Andrew, Woolcock, Kieran, Hanke, Daniel, Laidlaw, Stephen, Malik, Zainab, Nguyen, Dung, Provine, Nicholas, Tipton, Tom, Walker, Victoria, Goodyear, Carl S, Patel, Amit, Barnes, Eleanor, Willicombe, Michelle, Siebert, Stefan, de Silva, Thushan I, Snowden, John A, Lim, Sean H, Bowden, Sarah J, Billingham, Lucinda, Richter, Alex, Carroll, Miles, Carr, Edward J, Beale, Rupert, Rea, Daniel, Parry, Helen, Pirrie, Sarah, Lim, Zixiang, Satsangi, Jack, Dunachie, Susanna J, Cook, Gordon, Miller, Paul, Basu, Neil, Gilmour, Ashley, Hodgkins, Anne-Marie, Evans, Lili, Hughes, Ana, Longet, Stephanie, Meacham, Georgina, Yong, Kwee L, A'Hearne, Matthew J, Koh, Mickey B C, Burns, Siobhan O, Orchard, Kim, Paterson, Caron, McIlroy, Graham, Murray, Sam M, Thomson, Tina, Dimitriadis, Stavros, Goulston, Lyndsey, Miller, Samantha, Keillor, Victoria, Prendecki, Maria, Thomas, David, Kirkham, Amanda, McInnes, Iain B, and Kearns, Pamela

Published
2024
Full Text
View/download PDF

3. Spatial dysregulation of T follicular helper cells impairs vaccine responses in aging

Author

Silva-Cayetano, Alyssa, Fra-Bido, Sigrid, Robert, Philippe A., Innocentin, Silvia, Burton, Alice R., Watson, Emily M., Lee, Jia Le, Webb, Louise M. C., Foster, William S., McKenzie, Ross C. J., Bignon, Alexandre, Vanderleyden, Ine, Alterauge, Dominik, Lemos, Julia P., Carr, Edward J., Hill, Danika L., Cinti, Isabella, Balabanian, Karl, Baumjohann, Dirk, Espeli, Marion, Meyer-Hermann, Michael, Denton, Alice E., and Linterman, Michelle A.

Published
2023
Full Text
View/download PDF

5. Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes

Author

Tut, Gokhan, Lancaster, Tara, Krutikov, Maria, Sylla, Panagiota, Bone, David, Spalkova, Eliska, Bentley, Christopher, Amin, Umayr, Jadir, Azar, Hulme, Samuel, Kaur, Nayandeep, Tut, Elif, Bruton, Rachel, Wu, Mary Y., Harvey, Ruth, Carr, Edward J., Beale, Rupert, Stirrup, Oliver, Shrotri, Madhumita, Azmi, Borscha, Fuller, Christopher, Baynton, Verity, Irwin-Singer, Aidan, Hayward, Andrew, Copas, Andrew, Shallcross, Laura, and Moss, Paul

Published
2023
Full Text
View/download PDF

6. Comparative effectiveness of two- and three-dose COVID-19 vaccination schedules involving AZD1222 and BNT162b2 in people with kidney disease: a linked OpenSAFELY and UK Renal Registry cohort study

Author

Parker, Edward P.K., Horne, Elsie M.F., Hulme, William J., Tazare, John, Zheng, Bang, Carr, Edward J., Loud, Fiona, Lyon, Susan, Mahalingasivam, Viyaasan, MacKenna, Brian, Mehrkar, Amir, Scanlon, Miranda, Santhakumaran, Shalini, Steenkamp, Retha, Goldacre, Ben, Sterne, Jonathan A.C., Nitsch, Dorothea, and Tomlinson, Laurie A.

Published
2023
Full Text
View/download PDF

8. Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study

Author

Atti, Ana, Insalata, Ferdinando, Carr, Edward J, Otter, Ashley D, Castillo-Olivares, Javier, Wu, Mary, Harvey, Ruth, Howell, Michael, Chan, Andrew, Lyall, Jonathan, Temperton, Nigel, Cantoni, Diego, da Costa, Kelly, Nadesalingam, Angalee, Taylor-Kerr, Andrew, Hettiarachchi, Nipunadi, Tranquillini, Caio, Hewson, Jacqueline, Cole, Michelle J, Foulkes, Sarah, Munro, Katie, Monk, Edward J M, Milligan, Iain D, Linley, Ezra, Chand, Meera A, Brown, Colin S, Islam, Jasmin, Semper, Amanda, Charlett, Andre, Heeney, Jonathan L, Beale, Rupert, Zambon, Maria, Hopkins, Susan, Brooks, Tim, and Hall, Victoria

Published
2022
Full Text
View/download PDF

10. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

Author

Goodyear, Carl S, primary, Patel, Amit, additional, Barnes, Eleanor, additional, Willicombe, Michelle, additional, Siebert, Stefan, additional, de Silva, Thushan I, additional, Snowden, John A, additional, Lim, Sean H, additional, Bowden, Sarah J, additional, Billingham, Lucinda, additional, Richter, Alex, additional, Carroll, Miles, additional, Carr, Edward J, additional, Beale, Rupert, additional, Rea, Daniel, additional, Parry, Helen, additional, Pirrie, Sarah, additional, Lim, Zixiang, additional, Satsangi, Jack, additional, Dunachie, Susanna J, additional, Cook, Gordon, additional, Miller, Paul, additional, Basu, Neil, additional, Gilmour, Ashley, additional, Hodgkins, Anne-Marie, additional, Evans, Lili, additional, Hughes, Ana, additional, Longet, Stephanie, additional, Meacham, Georgina, additional, Yong, Kwee L, additional, A'Hearne, Matthew J, additional, Koh, Mickey B C, additional, Burns, Siobhan O, additional, Orchard, Kim, additional, Paterson, Caron, additional, McIlroy, Graham, additional, Murray, Sam M, additional, Thomson, Tina, additional, Dimitriadis, Stavros, additional, Goulston, Lyndsey, additional, Miller, Samantha, additional, Keillor, Victoria, additional, Prendecki, Maria, additional, Thomas, David, additional, Kirkham, Amanda, additional, McInnes, Iain B, additional, Kearns, Pamela, additional, Beesley, Richard, additional, Churchill, Vicky, additional, Insch, Elspeth, additional, Loughton, Holly, additional, MacDonald, Eilean, additional, Lax, Siân, additional, Lowe, Faye, additional, Magwaro, Sophia, additional, Gradwell, Mark, additional, Kinsella, Francesca, additional, Rolfe, Hayley, additional, McIntyre, Stacey, additional, Mortimer, Paige, additional, Al-Taei, Saly, additional, Tadros, Susan, additional, Workman, Sarita, additional, Arnott, Maxine, additional, Brock, James, additional, Melville, Andrew, additional, Najm, Aurelie, additional, Rutherford, Matthew, additional, Sunzini, Flavia, additional, Herman, Lou S, additional, Hobbs, Agnieszka, additional, Ragno, Martina, additional, Wu, Mary Y, additional, Selby, Rachael, additional, Clay, Jennifer, additional, Hutchison, Clare, additional, Lown, Robert, additional, Lwin, May N, additional, Meardon, Naomi, additional, Kelleher, Peter, additional, Lightstone, Liz, additional, Walters, Thomas, additional, Denyer, Jayne, additional, Ibrahim, Rahima, additional, Gleeson, Sarah, additional, Martin, Paul, additional, McAdoo, Stephen, additional, Baker, Helena, additional, Horswill, Sarah, additional, Parungao, Nina, additional, Saich, Stephen, additional, Cullinane, James, additional, Irwin, Sophie, additional, Klenerman, Paul, additional, Marjot, Thomas, additional, Chakraverty, Ronjon, additional, Holroyd, Christopher, additional, Kavi, Janki, additional, Trown, Doreen, additional, Babbage, Gavin, additional, Chackathayil, Julia, additional, Faria, Patricia, additional, Ingham, Karen, additional, Miah, Murad, additional, Miranda, Mauro, additional, O'Reilly, Nicola, additional, Smith, Callie, additional, Driver, Kimberley, additional, Gauntlett, Kaylee, additional, Farthing, Andrew, additional, Rundell, Suzann, additional, Smith, Emily, additional, Tong, Andrew, additional, Woolcock, Kieran, additional, Hanke, Daniel, additional, Laidlaw, Stephen, additional, Malik, Zainab, additional, Nguyen, Dung, additional, Provine, Nicholas, additional, Tipton, Tom, additional, and Walker, Victoria, additional

Published
2024
Full Text
View/download PDF

11. Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants

Author

Russell, Timothy W., Townsley, Hermaleigh, Abbott, Sam, Hellewell, Joel, Carr, Edward J., Chapman, Lloyd A. C., Pung, Rachael, Quilty, Billy J., Hodgson, David, Fowler, Ashley S., Adams, Lorin, Bailey, Chris, Mears, Harriet V., Harvey, Ruth, Clayton, Bobbi, O’Reilly, Nicola, Ngai, Yenting, Nicod, Jerome, Gamblin, Steve, Williams, Bryan, Gandhi, Sonia, Swanton, Charles, Beale, Rupert, Bauer, David L. V., Wall, Emma C., Kucharski, Adam J., Russell, Timothy W., Townsley, Hermaleigh, Abbott, Sam, Hellewell, Joel, Carr, Edward J., Chapman, Lloyd A. C., Pung, Rachael, Quilty, Billy J., Hodgson, David, Fowler, Ashley S., Adams, Lorin, Bailey, Chris, Mears, Harriet V., Harvey, Ruth, Clayton, Bobbi, O’Reilly, Nicola, Ngai, Yenting, Nicod, Jerome, Gamblin, Steve, Williams, Bryan, Gandhi, Sonia, Swanton, Charles, Beale, Rupert, Bauer, David L. V., Wall, Emma C., and Kucharski, Adam J.

Abstract

The emergence of successive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) during 2020 to 2022, each exhibiting increased epidemic growth relative to earlier circulating variants, has created a need to understand the drivers of such growth. However, both pathogen biology and changing host characteristics—such as varying levels of immunity—can combine to influence replication and transmission of SARS-CoV-2 within and between hosts. Disentangling the role of variant and host in individual-level viral shedding of VOCs is essential to inform Coronavirus Disease 2019 (COVID-19) planning and response and interpret past epidemic trends. Using data from a prospective observational cohort study of healthy adult volunteers undergoing weekly occupational health PCR screening, we developed a Bayesian hierarchical model to reconstruct individual-level viral kinetics and estimate how different factors shaped viral dynamics, measured by PCR cycle threshold (Ct) values over time. Jointly accounting for both interindividual variation in Ct values and complex host characteristics—such as vaccination status, exposure history, and age—we found that age and number of prior exposures had a strong influence on peak viral replication. Older individuals and those who had at least 5 prior antigen exposures to vaccination and/or infection typically had much lower levels of shedding. Moreover, we found evidence of a correlation between the speed of early shedding and duration of incubation period when comparing different VOCs and age groups. Our findings illustrate the value of linking information on participant characteristics, symptom profile and infecting variant with prospective PCR sampling, and the importance of accounting for increasingly complex population exposure landscapes when analysing the viral kinetics of VOCs. Trial Registration: The Legacy study is a prospective observational cohort study of healthy adult volunteers undergoing weekly oc

Published
2024

13. Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants

Author

Russell, Timothy W., primary, Townsley, Hermaleigh, additional, Abbott, Sam, additional, Hellewell, Joel, additional, Carr, Edward J., additional, Chapman, Lloyd A. C., additional, Pung, Rachael, additional, Quilty, Billy J., additional, Hodgson, David, additional, Fowler, Ashley S., additional, Adams, Lorin, additional, Bailey, Chris, additional, Mears, Harriet V., additional, Harvey, Ruth, additional, Clayton, Bobbi, additional, O’Reilly, Nicola, additional, Ngai, Yenting, additional, Nicod, Jerome, additional, Gamblin, Steve, additional, Williams, Bryan, additional, Gandhi, Sonia, additional, Swanton, Charles, additional, Beale, Rupert, additional, Bauer, David L. V., additional, Wall, Emma C., additional, and Kucharski, Adam J., additional

Published
2024
Full Text
View/download PDF

14. SARS-CoV-2 mucosal neutralising immunity after vaccination

Author

Carr, Edward J, primary, Dowgier, Guilia, additional, Greenwood, David, additional, Herman, Lou S, additional, Hobbs, Agnieszka, additional, Ragno, Martina, additional, Stevenson-Leggett, Phoebe, additional, Gahir, Joshua, additional, Townsley, Hermaleigh, additional, Harvey, Ruth, additional, Bailey, Chris, additional, Fowler, Ashley S, additional, Miah, Murad, additional, Smith, Callie, additional, Miranda, Mauro, additional, Bawumia, Philip, additional, Mears, Harriet V, additional, Adams, Lorin, additional, Hatipoglu, Emine, additional, O'Reilly, Nicola, additional, Warchal, Scott, additional, Sawyer, Chelsea, additional, Ambrose, Karen, additional, Strange, Amy, additional, Kelly, Gavin, additional, Beale, Rupert, additional, Papineni, Padmasayee, additional, Corrah, Tumena, additional, Gilson, Richard, additional, Gamblin, Steve, additional, Kassiotis, George, additional, Libri, Vincenzo, additional, Williams, Bryan, additional, Swanton, Charles, additional, Gandhi, Sonia, additional, Bauer, David L V, additional, Wall, Emma, additional, and Wu, Mary Y, additional

Published
2023
Full Text
View/download PDF

15. 34 COVID-19 caused by either Omicron sub-variants or Delta in non-hospitalised adults associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history

Author

Townsley, Hermaleigh, primary, Gahir, Joshua, additional, Russell, Timothy W., additional, Carr, Edward J., additional, Dyke, Matala, additional, Adams, Lorin, additional, Miah, Murad, additional, Clayton, Bobbi, additional, Smith, Callie, additional, Miranda, Mauro, additional, Mears, Harriet V., additional, Bailey, Chris, additional, Black, James R.M., additional, Fowler, Ashley S., additional, Crawford, Margaret, additional, Wilkinson, Katalin, additional, Hutchinson, Matthew, additional, Harvey, Ruth, additional, O'Reilly, Nicola, additional, Kelly, Gavin, additional, Goldstone, Robert, additional, Beale, Rupert, additional, Papineni, Padmasayee, additional, Corrah, Tumenah, additional, Gilson, Richard, additional, Caidan, Simon, additional, Nicod, Jerome, additional, Gamblin, Steve, additional, Kassiotis, George, additional, Libri, Vincenzo, additional, Williams, Bryan, additional, Gandhi, Sonia, additional, Kucharski, Adam J., additional, Swanton, Charles, additional, Bauer, David L.V., additional, and Wall, Emma C., additional

Published
2023
Full Text
View/download PDF

16. COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.

Author

Townsley, Hermaleigh, Gahir, Joshua, Russell, Timothy W., Greenwood, David, Carr, Edward J., Dyke, Matala, Adams, Lorin, Miah, Murad, Clayton, Bobbi, Smith, Callie, Miranda, Mauro, Mears, Harriet V., Bailey, Chris, Black, James R. M., Fowler, Ashley S., Crawford, Margaret, Wilkinson, Katalin, Hutchinson, Matthew, Harvey, Ruth, and O'Reilly, Nicola

Subjects
SARS-CoV-2 Omicron variant, VACCINATION status, SARS-CoV-2 Delta variant, COUGH, FEVER, COVID-19, SARS-CoV-2
Abstract

Background: SARS-CoV-2 variant Omicron rapidly evolved over 2022, causing three waves of infection due to sub-variants BA.1, BA.2 and BA.4/5. We sought to characterise symptoms and viral loads over the course of COVID-19 infection with these sub-variants in otherwise-healthy, vaccinated, non-hospitalised adults, and compared data to infections with the preceding Delta variant of concern (VOC). Methods: In a prospective, observational cohort study, healthy vaccinated UK adults who reported a positive polymerase chain reaction (PCR) or lateral flow test, self-swabbed on alternate weekdays until day 10. We compared participant-reported symptoms and viral load trajectories between infections caused by VOCs Delta and Omicron (sub-variants BA.1, BA.2 or BA.4/5), and tested for relationships between vaccine dose, symptoms and PCR cycle threshold (Ct) as a proxy for viral load using Chi-squared (χ2) and Wilcoxon tests. Results: 563 infection episodes were reported among 491 participants. Across infection episodes, there was little variation in symptom burden (4 [IQR 3–5] symptoms) and duration (8 [IQR 6–11] days). Whilst symptom profiles differed among infections caused by Delta compared to Omicron sub-variants, symptom profiles were similar between Omicron sub-variants. Anosmia was reported more frequently in Delta infections after 2 doses compared with Omicron sub-variant infections after 3 doses, for example: 42% (25/60) of participants with Delta infection compared to 9% (6/67) with Omicron BA.4/5 (χ2 P < 0.001; OR 7.3 [95% CI 2.7–19.4]). Fever was less common with Delta (20/60 participants; 33%) than Omicron BA.4/5 (39/67; 58%; χ2 P = 0.008; OR 0.4 [CI 0.2–0.7]). Amongst infections with an Omicron sub-variants, symptoms of coryza, fatigue, cough and myalgia predominated. Viral load trajectories and peaks did not differ between Delta, and Omicron, irrespective of symptom severity (including asymptomatic participants), VOC or vaccination status. PCR Ct values were negatively associated with time since vaccination in participants infected with BA.1 (β = -0.05 (CI -0.10–0.01); P = 0.031); however, this trend was not observed in BA.2 or BA.4/5 infections. Conclusion: Our study emphasises both the changing symptom profile of COVID-19 infections in the Omicron era, and ongoing transmission risk of Omicron sub-variants in vaccinated adults. Trial registration: NCT04750356. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest London

Author

Bailey, Chris, primary, Sanderson, Theo, additional, Townsley, Hermaleigh, additional, Goldman, Jacki, additional, Black, James R M, additional, Young, George, additional, Goldstone, Robert, additional, Fowler, Ashley S, additional, Ward, Sophia, additional, Jackson, Deborah J, additional, Cubitt, Laura, additional, Dearing, Vicky, additional, O'Neil, Olga, additional, Crawford, Marg, additional, Snell, Daniel, additional, Finadis, Makis, additional, Edwards, Amelia, additional, Perez-Lloret, Jimena, additional, Gahir, Joshua, additional, Carr, Edward J, additional, Riddell, Andy, additional, Aitken, Jim, additional, Ambrose, Karen, additional, Sawyer, Chelsea, additional, O'Reilly, Nicola, additional, Caidan, Simon, additional, Wu, Mary Y, additional, Walker, Philip A, additional, Hindmarsh, Steve, additional, Howell, Michael, additional, Jordan, Andrew, additional, Fleming, James, additional, Houlihan, Catherine, additional, Nastouli, Eleni, additional, Moores, Rachel, additional, Hsu, Desmond, additional, Papineni, Padmasayee, additional, Corrah, Tumena, additional, Gilson, Richard, additional, MacRae, James, additional, Hubank, Michael, additional, Van As, Nicholas, additional, Turajlic, Samra, additional, Beale, Rupert, additional, Levi, Marcel, additional, Barrell, Sam, additional, Williams, Bryan, additional, Gamblin, Steve, additional, Nicod, Jerome, additional, Gandhi, Sonia, additional, Bauer, David L V, additional, Wall, Emma C, additional, and Swanton, Charles, additional

Published
2023
Full Text
View/download PDF

19. Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection

Author

Carr, Edward J, primary, Wu, Mary Y, additional, Gahir, Joshua, additional, Harvey, Ruth, additional, Townsley, Hermaleigh, additional, Bailey, Chris, additional, Fowler, Ashley S, additional, Dowgier, Giulia, additional, Hobbs, Agnieszka, additional, Herman, Lou, additional, Ragno, Martina, additional, Miah, Murad, additional, Bawumia, Phillip, additional, Smith, Callie, additional, Miranda, Mauro, additional, Mears, Harriet V, additional, Adams, Lorin, additional, Haptipoglu, Emine, additional, O’Reilly, Nicola, additional, Warchal, Scott, additional, Sawyer, Chelsea, additional, Ambrose, Karen, additional, Kelly, Gavin, additional, Beale, Rupert, additional, Papineni, Padmasayee, additional, Corrah, Tumena, additional, Gilson, Richard, additional, Gamblin, Steve, additional, Kassiotis, George, additional, Libri, Vincenzo, additional, Williams, Bryan, additional, Swanton, Charles, additional, Gandhi, Sonia, additional, LV Bauer, David, additional, and Wall, Emma C, additional

Published
2023
Full Text
View/download PDF

20. Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein

Author

Upasani, Vinit, primary, Townsend, Katie, additional, Wu, Mary Y, additional, Carr, Edward J, additional, Hobbs, Agnieszka, additional, Dowgier, Giulia, additional, Ragno, Martina, additional, Herman, Lou S, additional, Sharma, Sonal, additional, Shah, Devesh, additional, Lee, Simon F K, additional, Chauhan, Neil, additional, Glanville, Julie M, additional, Neave, Lucy, additional, Hanson, Steven, additional, Ravichandran, Sriram, additional, Tynan, Aoife, additional, O’Sullivan, Mary, additional, Moreira, Fernando, additional, Workman, Sarita, additional, Symes, Andrew, additional, Burns, Siobhan O, additional, Tadros, Susan, additional, Hart, Jennifer C L, additional, Beale, Rupert C L, additional, Gandhi, Sonia, additional, Wall, Emma C, additional, McCoy, Laura, additional, and Lowe, David M, additional

Published
2023
Full Text
View/download PDF

23. Chronogram: an R package for data curation and analysis of infection and vaccination cohort studies.

Author

Greenwood, David, Shawe-Taylor, Marianne, Townsley, Hermaleigh, Gahir, Joshua, Sahadeo, Nikita, Alhassan, Yakubu, Chaloner, Charlotte, Galgut, Oliver, Kelly, Gavin, Bauer, David L V, Wall, Emma C, Wu, Mary Y, and Carr, Edward J

Subjects
VACCINE effectiveness, ANTIBODY formation, DATABASES, DATA curation, SCIENTIFIC observation
Abstract

Motivation Observational cohort studies that track vaccine and infection responses offer real-world data to inform pandemic policy. Translating biological hypotheses, such as whether different patterns of accumulated antigenic exposures confer differing antibody responses, into analysis code can be onerous, particularly when source data is dis-aggregated. Results The R package chronogram introduces the class chronogram, where metadata is seamlessly aggregated with sparse infection episode, clinical and laboratory data. Each experimental modality is added sequentially, allowing the incorporation of new data, such as specialized time-consuming research assays, or their downstream analyses. Source data can be any rectangular data format, including database tables (such as structured query language databases). This supports annotations that aggregate data types/sources, for example, combining symptoms, molecular testing, and sequencing of one or more infectious episodes in a pathogen-agnostic manner. Chronogram arranges observational data to allow the translation of biological hypotheses into their corresponding code via a shared vocabulary. Availability and implementation Chronogram is implemented R and available under an MIT licence at: https://www.github.com/FrancisCrickInstitute/chronogram ; a user manual is available at: https://franciscrickinstitute.github.io/chronogram/ [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Dichotomy of neutralizing antibody, B cell and T cell responses to SARS-CoV-2 vaccination and protection in healthy adults

Author

Carr, Edward J, primary, Townsley, Hermaleigh, additional, Wu, Mary Y, additional, Wilkinson, Katalin A, additional, Hobson, Philip S, additional, Levi, Dina, additional, Namjou, Sina, additional, Mears, Harriet V, additional, Hobbs, Agnieszka, additional, Ragno, Martina, additional, Herman, Lou S, additional, Harvey, Ruth, additional, Bailey, Chris, additional, Fowler, Ashley S, additional, Hatipoglu, Emine, additional, Ngai, Yenting, additional, Clayton, Bobbi, additional, Miah, Murad, additional, Bawumia, Philip, additional, Miranda, Mauro, additional, Smith, Callie, additional, Sawyer, Chelsea, additional, Kelly, Gavin, additional, Mahalingasivam, Viyaasan, additional, Zheng, Bang, additional, Evans, Stephen JW, additional, Libri, Vincenzo, additional, Riddell, Andrew, additional, Nicod, Jerome, additional, O'Reilly, Nicola, additional, Howell, Michael, additional, Williams, Bryan, additional, Wilkinson, Robert J, additional, Kassiotis, George, additional, Swanton, Charles, additional, Gandhi, Sonia, additional, Beale, Rupert CL, additional, Bauer, David LV, additional, and Wall, Emma C, additional

Published
2023
Full Text
View/download PDF

25. Within-host SARS-CoV-2 viral kinetics informed by complex life course exposures reveals different intrinsic properties of Omicron and Delta variants

Author

Russell, Timothy W, primary, Townsley, Hermaleigh, additional, Abbott, Sam, additional, Hellewell, Joel, additional, Carr, Edward J, additional, Chapman, Lloyd, additional, Pung, Rachael, additional, Quilty, Billy J, additional, Hodgson, David, additional, Fowler, Ashley, additional, Adams, Lorin, additional, Bailey, Christopher, additional, Mears, Harriet V, additional, Harvey, Ruth, additional, Clayton, Bobbi, additional, O'Reilly, Nicola, additional, Ngai, Yenting, additional, Nicod, Jerome, additional, Gamblin, Steve, additional, Williams, Bryan, additional, Gandhi, Sonia, additional, Swanton, Charles, additional, Beale, Rupert, additional, Bauer, David LV, additional, Wall, Emma C, additional, and Kucharski, Adam, additional

Published
2023
Full Text
View/download PDF

26. Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer

Author

Wu, Mary Y., primary, Shepherd, Scott T.C., additional, Fendler, Annika, additional, Carr, Edward J., additional, Au, Lewis, additional, Harvey, Ruth, additional, Dowgier, Giulia, additional, Hobbs, Agnieszka, additional, Herman, Lou S., additional, Ragno, Martina, additional, Adams, Lorin, additional, Schmitt, Andreas M., additional, Tippu, Zayd, additional, Shum, Benjamin, additional, Farag, Sheima, additional, Rogiers, Aljosja, additional, O’Reilly, Nicola, additional, Bawumia, Philip, additional, Smith, Callie, additional, Carlyle, Eleanor, additional, Edmonds, Kim, additional, Del Rosario, Lyra, additional, Lingard, Karla, additional, Mangwende, Mary, additional, Holt, Lucy, additional, Ahmod, Hamid, additional, Korteweg, Justine, additional, Foley, Tara, additional, Barber, Taja, additional, Hepworth, Stephanie, additional, Emslie-Henry, Andrea, additional, Caulfield-Lynch, Niamh, additional, Byrne, Fiona, additional, Deng, Daqi, additional, Williams, Bryan, additional, Brown, Michael, additional, Caidan, Simon, additional, Gavrielides, Mike, additional, MacRae, James I., additional, Kelly, Gavin, additional, Peat, Kema, additional, Kelly, Denise, additional, Murra, Aida, additional, Kelly, Kayleigh, additional, O’Flaherty, Molly, additional, Popat, Sanjay, additional, Yousaf, Nadia, additional, Jhanji, Shaman, additional, Tatham, Kate, additional, Cunningham, David, additional, Van As, Nicholas, additional, Young, Kate, additional, Furness, Andrew J.S., additional, Pickering, Lisa, additional, Beale, Rupert, additional, Swanton, Charles, additional, Gandhi, Sonia, additional, Gamblin, Steve, additional, Bauer, David L.V., additional, Kassiotis, George, additional, Howell, Michael, additional, Walker, Susanna, additional, Nicholson, Emma, additional, Larkin, James, additional, Wall, Emma C., additional, and Turajlic, Samra, additional

Published
2023
Full Text
View/download PDF

28. Factors associated with COVID-19 vaccine uptake in people with kidney disease: an OpenSAFELY cohort study

Author

Collaborative, The OpenSAFELY, Parker, Edward PK, Tazare, John, Hulme, William J, Bates, Christopher, Carr, Edward J, Cockburn, Jonathan, Curtis, Helen J, Fisher, Louis, Green, Amelia CA, Harper, Sam, Hester, Frank, Horne, Elsie MF, Loud, Fiona, Lyon, Susan, Mahalingasivam, Viyaasan, Mehrkar, Amir, Nab, Linda, Parry, John, Santhakumaran, Shalini, Steenkamp, Retha, Sterne, Jonathan AC, Walker, Alex J, Williamson, Elizabeth J, Willicombe, Michelle, Zheng, Bang, Goldacre, Ben, Nitsch, Dorothea, and Tomlinson, Laurie A

Subjects
FOS: Clinical medicine, Immunology, Infectious Disease, Cell Biology
Abstract

Objective To characterise factors associated with COVID-19 vaccine uptake among people with kidney disease in England. Design Retrospective cohort study using the OpenSAFELY-TPP platform, performed with the approval of NHS England. Setting Individual-level routine clinical data from 24 million people across GPs in England using TPP software. Primary care data were linked directly with COVID-19 vaccine records up to 31 August 2022 and with renal replacement therapy (RRT) status via the UK Renal Registry (UKRR). Participants A cohort of adults with stage 3–5 chronic kidney disease (CKD) or receiving RRT at the start of the COVID-19 vaccine roll-out was identified based on evidence of reduced estimated glomerular filtration rate (eGFR) or inclusion in the UKRR. Main outcome measures Dose-specific vaccine coverage over time was determined from 1 December 2020 to 31 August 2022. Individual-level factors associated with receipt of a 3-dose or 4-dose vaccine series were explored via Cox proportional hazards models. Results 992 205 people with stage 3–5 CKD or receiving RRT were included. Cumulative vaccine coverage as of 31 August 2022 was 97.5%, 97.0% and 93.9% for doses 1, 2 and 3, respectively, and 81.9% for dose 4 among individuals with one or more indications for eligibility. Delayed 3-dose vaccine uptake was associated with younger age, minority ethnicity, social deprivation and severe mental illness—associations that were consistent across CKD severity subgroups, dialysis patients and kidney transplant recipients. Similar associations were observed for 4-dose uptake. Conclusion Although high primary vaccine and booster dose coverage has been achieved among people with kidney disease in England, key disparities in vaccine uptake remain across clinical and demographic groups and 4-dose coverage is suboptimal. Targeted interventions are needed to identify barriers to vaccine uptake among under-vaccinated subgroups identified in the present study.

Published
2023
Full Text
View/download PDF

29. Comparative effectiveness of two- and three-dose COVID-19 vaccination schedules involving AZD1222 and BNT162b2 in people with kidney disease: a linked OpenSAFELY and UK Renal Registry cohort study

Author

Collaborative, The OpenSAFELY, Parker, Edward PK, Horne, Elsie MF, Hulme, William J, Tazare, John, Zheng, Bang, Carr, Edward J, Loud, Fiona, Lyon, Susan, Mahalingasivam, Viyaasan, MacKenna, Brian, Mehrkar, Amir, Scanlon, Miranda, Santhakumaran, Shalini, Steenkamp, Retha, Goldacre, Ben, Sterne, Jonathan AC, Nitsch, Dorothea, Tomlinson, Laurie A, and Collaborative, The LH&W NCS

Subjects
FOS: Clinical medicine, Immunology, Infectious Disease, Cell Biology
Abstract

Background: Kidney disease is a key risk factor for COVID-19-related mortality and suboptimal vaccine response. Optimising vaccination strategies is essential to reduce the disease burden in this vulnerable population. We therefore compared the effectiveness of two- and three-dose schedules involving AZD1222 (AZ; ChAdOx1-S) and BNT162b2 (BNT) among people with kidney disease in England. Methods: With the approval of NHS England, we performed a retrospective cohort study among people with moderate-to-severe kidney disease. Using linked primary care and UK Renal Registry records in the OpenSAFELY-TPP platform, we identified adults with stage 3–5 chronic kidney disease, dialysis recipients, and kidney transplant recipients. We used Cox proportional hazards models to compare COVID-19-related outcomes and non-COVID-19 death after two-dose (AZ–AZ vs BNT–BNT) and three-dose (AZ–AZ–BNT vs BNT–BNT–BNT) schedules. Findings: After two doses, incidence during the Delta wave was higher in AZ–AZ (n = 257,580) than BNT–BNT recipients (n = 169,205; adjusted hazard ratios [95% CIs] 1.43 [1.37–1.50], 1.59 [1.43–1.77], 1.44 [1.12–1.85], and 1.09 [1.02–1.17] for SARS-CoV-2 infection, COVID-19-related hospitalisation, COVID-19-related death, and non-COVID-19 death, respectively). Findings were consistent across disease subgroups, including dialysis and transplant recipients. After three doses, there was little evidence of differences between AZ–AZ–BNT (n = 220,330) and BNT–BNT–BNT recipients (n = 157,065) for any outcome during a period of Omicron dominance. Interpretation: Among individuals with moderate-to-severe kidney disease, two doses of BNT conferred stronger protection than AZ against SARS-CoV-2 infection and severe disease. A subsequent BNT dose levelled the playing field, emphasising the value of heterologous RNA doses in vulnerable populations. Funding: National Core Studies, Wellcome Trust, MRC, and Health Data Research UK.

Published
2023
Full Text
View/download PDF

30. Immunogenicity of SARSCoV2 Third Dose Vaccine Strategies in Immunocompromised Patients with Suboptimal Immunity Following Two Doses (OCTAVE-DUO): An Open-Label, Multi-Centre, Randomised, Controlled Phase III Trial

Author

Goodyear, Carl S., primary, Patel, Amit, additional, Barnes, Eleanor, additional, willicombe, michelle, additional, Siebert, Stefan, additional, de Silva, Thushan I., additional, Snowden, John A., additional, Lim, Sean, additional, Bowden, Sarah, additional, Billingham, Lucinda J., additional, Richter, Alex G., additional, Carroll, Miles W., additional, Carr, Edward J., additional, Beale, Rupert, additional, Rea, Daniel, additional, Parry, Helen, additional, Pirrie, Sarah, additional, Lim, Zixiang, additional, Satsangi, Jack, additional, Dunachie, Susanna, additional, Cook, Gordon, additional, Miller, Paul, additional, Basu, Neil, additional, Gilmour, Ashley, additional, Hodgkins, Anne-Marie, additional, Evans, Lili, additional, Hughes, Ana, additional, Longet, Stephanie, additional, Meacham, Georgina, additional, Yong, Kwee, additional, Ahearne, Matthew, additional, Koh, Mickey B. C., additional, Burns, Siobhan O., additional, Orchard, Kim, additional, Paterson, Caron, additional, McIlroy, Graham, additional, Murray, Sam M., additional, Thomson, Tina, additional, Dimitriadis, Stavros, additional, Goulston, Lyndsey, additional, Miller, Samantha, additional, Keillor, Victoria, additional, Prendecki, Maria, additional, Thomas, David, additional, Kirkham, Amanda, additional, McInnes, Iain, additional, and Kearns, Pamela, additional

Published
2023
Full Text
View/download PDF

31. Antibody Correlates of Protection Against Delta Infection after Vaccination: A Nested Case-Control within the UK-Based Siren Study

Author

Atti, Ana, primary, Insalata, Ferdinando, additional, Carr, Edward J., additional, Otter, Ashley, additional, Foulkes, Sarah, additional, Wu, Mary Y., additional, Cole, Michelle, additional, Linley, Ezra, additional, Semper, Amanda, additional, Brooks, Tim, additional, Hopkins, Susan, additional, Charlett, Andre, additional, Beale, Rupert, additional, and Hall, Victoria Jane, additional

Published
2023
Full Text
View/download PDF

32. WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed

Author

Wu, Mary Y, primary, Carr, Edward J, additional, Harvey, Ruth, additional, Mears, Harriet V, additional, Kjaer, Svend, additional, Townsley, Hermaleigh, additional, Hobbs, Agnieszka, additional, Ragno, Martina, additional, Herman, Lou S, additional, Adams, Lorin, additional, Gamblin, Steve, additional, Howell, Michael, additional, Beale, Rupert, additional, Brown, Michael, additional, Williams, Bryan, additional, Gandhi, Sonia, additional, Swanton, Charles, additional, Wall, Emma C, additional, and Bauer, David L V, additional

Published
2022
Full Text
View/download PDF

33. Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the OpenSAFELY-UKRR and SRR databases.

Author

Zheng, Bang, Campbell, Jacqueline, Carr, Edward J, Tazare, John, Nab, Linda, Mahalingasivam, Viyaasan, Mehrkar, Amir, Santhakumaran, Shalini, Steenkamp, Retha, Loud, Fiona, Lyon, Susan, Scanlon, Miranda, Hulme, William J, Green, Amelia C A, Curtis, Helen J, Fisher, Louis, Parker, Edward, Goldacre, Ben, Douglas, Ian, and Evans, Stephen

Subjects
RENAL replacement therapy, MOLNUPIRAVIR, COVID-19, PROPORTIONAL hazards models, TREATMENT effectiveness
Abstract

Background Due to limited inclusion of patients on kidney replacement therapy (KRT) in clinical trials, the effectiveness of coronavirus disease 2019 (COVID-19) therapies in this population remains unclear. We sought to address this by comparing the effectiveness of sotrovimab against molnupiravir, two commonly used treatments for non-hospitalised KRT patients with COVID-19 in the UK. Methods With the approval of National Health Service England, we used routine clinical data from 24 million patients in England within the OpenSAFELY-TPP platform linked to the UK Renal Registry (UKRR) to identify patients on KRT. A Cox proportional hazards model was used to estimate hazard ratios (HRs) of sotrovimab versus molnupiravir with regards to COVID-19-related hospitalisations or deaths in the subsequent 28 days. We also conducted a complementary analysis using data from the Scottish Renal Registry (SRR). Results Among the 2367 kidney patients treated with sotrovimab (n  = 1852) or molnupiravir (n  = 515) between 16 December 2021 and 1 August 2022 in England, 38 cases (1.6%) of COVID-19-related hospitalisations/deaths were observed. Sotrovimab was associated with substantially lower outcome risk than molnupiravir {adjusted HR 0.35 [95% confidence interval (CI) 0.17–0.71]; P  = .004}, with results remaining robust in multiple sensitivity analyses. In the SRR cohort, sotrovimab showed a trend toward lower outcome risk than molnupiravir [HR 0.39 (95% CI 0.13–1.21); P  = .106]. In both datasets, sotrovimab had no evidence of an association with other hospitalisation/death compared with molnupiravir (HRs ranged from 0.73 to 1.29; P  > .05). Conclusions In routine care of non-hospitalised patients with COVID-19 on KRT, sotrovimab was associated with a lower risk of severe COVID-19 outcomes compared with molnupiravir during Omicron waves. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer

Author

Fendler, Annika, primary, Shepherd, Scott T.C., additional, Au, Lewis, additional, Wu, Mary, additional, Harvey, Ruth, additional, Wilkinson, Katalin A., additional, Schmitt, Andreas M., additional, Tippu, Zayd, additional, Shum, Benjamin, additional, Farag, Sheima, additional, Rogiers, Aljosja, additional, Carlyle, Eleanor, additional, Edmonds, Kim, additional, Del Rosario, Lyra, additional, Lingard, Karla, additional, Mangwende, Mary, additional, Holt, Lucy, additional, Ahmod, Hamid, additional, Korteweg, Justine, additional, Foley, Tara, additional, Barber, Taja, additional, Emslie-Henry, Andrea, additional, Caulfield-Lynch, Niamh, additional, Byrne, Fiona, additional, Deng, Daqi, additional, Kjaer, Svend, additional, Song, Ok-Ryul, additional, Queval, Christophe J., additional, Kavanagh, Caitlin, additional, Wall, Emma C., additional, Carr, Edward J., additional, Caidan, Simon, additional, Gavrielides, Mike, additional, MacRae, James I., additional, Kelly, Gavin, additional, Peat, Kema, additional, Kelly, Denise, additional, Murra, Aida, additional, Kelly, Kayleigh, additional, O’Flaherty, Molly, additional, Shea, Robyn L., additional, Gardner, Gail, additional, Murray, Darren, additional, Popat, Sanjay, additional, Yousaf, Nadia, additional, Jhanji, Shaman, additional, Tatham, Kate, additional, Cunningham, David, additional, Van As, Nicholas, additional, Young, Kate, additional, Furness, Andrew J.S., additional, Pickering, Lisa, additional, Beale, Rupert, additional, Swanton, Charles, additional, Gandhi, Sonia, additional, Gamblin, Steve, additional, Bauer, David L.V., additional, Kassiotis, George, additional, Howell, Michael, additional, Nicholson, Emma, additional, Walker, Susanna, additional, Wilkinson, Robert J., additional, Larkin, James, additional, and Turajlic, Samra, additional

Published
2022
Full Text
View/download PDF

36. The impact of Omicron on outcomes following infection with SARS-CoV-2 in patients with kidney failure in Scotland

Author

Bell, Samira, primary, Campbell, Jacqueline, additional, Watters, Chrissie, additional, O'Neil, Martin, additional, Almond, Alison, additional, Buck, Katharine, additional, Carr, Edward J, additional, Cousland, Zoe, additional, Findlay, Mark, additional, Joss, Nicola, additional, Metcalfe, Wendy, additional, Spalding, Elaine, additional, Methven, Shona, additional, and Mark, Patrick B, additional

Published
2022
Full Text
View/download PDF

37. Non-hospitalised, vaccinated adults with COVID-19 caused by Omicron BA.1 and BA.2 present with changing symptom profiles compared to those with Delta despite similar viral kinetics

Author

Townsley, Hermaleigh, primary, Carr, Edward J, additional, Russell, Timothy W, additional, Adams, Lorin, additional, Mears, Harriet V, additional, Bailey, Chris, additional, Black, James RM, additional, Fowler, Ashley S, additional, Wilkinson, Katalin, additional, Hutchinson, Matthew, additional, Harvey, Ruth, additional, Clayton, Bobbi, additional, Kelly, Gavin, additional, Beale, Rupert, additional, Papineni, Padmasayee, additional, Corrah, Tumena, additional, Caidan, Simon, additional, Nicod, Jerome, additional, Gamblin, Steve, additional, Kassiotis, George, additional, Libri, Vincenzo, additional, Williams, Bryan, additional, Gandhi, Sonia, additional, Kucharski, Adam J, additional, Swanton, Charles, additional, Wall, Emma C, additional, and Bauer, David LV, additional

Published
2022
Full Text
View/download PDF

38. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

Author

Fendler, Annika, Shepherd, Scott T C, Au, Lewis, Wu, Mary, Harvey, Ruth, Schmitt, Andreas M, Tippu, Zayd, Shum, Benjamin, Farag, Sheima, Rogiers, Aljosja, Carlyle, Eleanor, Edmonds, Kim, Del Rosario, Lyra, Lingard, Karla, Mangwende, Mary, Holt, Lucy, Ahmod, Hamid, Korteweg, Justine, Foley, Tara, Barber, Taja, Emslie-Henry, Andrea, Caulfield-Lynch, Niamh, Byrne, Fiona, Deng, Daqi, Kjaer, Svend, Song, Ok-Ryul, Queval, Christophe, Kavanagh, Caitlin, Wall, Emma C, Carr, Edward J, Caidan, Simon, Gavrielides, Mike, MacRae, James I, Kelly, Gavin, Peat, Kema, Kelly, Denise, Murra, Aida, Kelly, Kayleigh, O'Flaherty, Molly, Shea, Robyn L, Gardner, Gail, Murray, Darren, Yousaf, Nadia, Jhanji, Shaman, Tatham, Kate, Cunningham, David, Van As, Nicholas, Young, Kate, Furness, Andrew J S, Pickering, Lisa, Beale, Rupert, Swanton, Charles, Gandhi, Sonia, Gamblin, Steve, Bauer, David L V, Kassiotis, George, Howell, Michael, Nicholson, Emma, Walker, Susanna, Larkin, James, and Turajlic, Samra

Published
2022
Full Text
View/download PDF

41. Three-dose vaccination elicits neutralising antibodies against omicron

Author

Wu, Mary, Wall, Emma C, Carr, Edward J, Harvey, Ruth, Townsley, Hermaleigh, Mears, Harriet V, Adams, Lorin, Kjaer, Svend, Kelly, Gavin, Warchal, Scott, Sawyer, Chelsea, Kavanagh, Caitlin, Queval, Christophe J, Ngai, Yenting, Hatipoglu, Emine, Ambrose, Karen, Hindmarsh, Steve, Beale, Rupert, Gamblin, Steve, Howell, Michael, Kassiotis, George, Libri, Vincenzo, Williams, Bryan, Gandhi, Sonia, Swanton, Charles, and Bauer, David LV

Published
2022
Full Text
View/download PDF

42. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer

Author

Fendler, Annika, Shepherd, Scott T.C., Au, Lewis, Wilkinson, Katalin A., Wu, Mary, Schmitt, Andreas M., Tippu, Zayd, Farag, Sheima, Rogiers, Aljosja, Harvey, Ruth, Carlyle, Eleanor, Edmonds, Kim, Del Rosario, Lyra, Lingard, Karla, Mangwende, Mary, Holt, Lucy, Ahmod, Hamid, Korteweg, Justine, Foley, Tara, Barber, Taja, Emslie-Henry, Andrea, Caulfield-Lynch, Niamh, Byrne, Fiona, Shum, Benjamin, Gerard, Camille L., Deng, Daqi, Kjaer, Svend, Song, Ok-Ryul, Queval, Christophe, Kavanagh, Caitlin, Wall, Emma C., Carr, Edward J., Namjou, Sina, Caidan, Simon, Gavrielides, Mike, MacRae, James I., Kelly, Gavin, Peat, Kema, Kelly, Denise, Murra, Aida, Kelly, Kayleigh, O’Flaherty, Molly, Shea, Robyn L., Gardner, Gail, Murray, Darren, Popat, Sanjay, Yousaf, Nadia, Jhanji, Shaman, Van As, Nicholas, Young, Kate, Furness, Andrew J.S., Pickering, Lisa, Beale, Rupert, Swanton, Charles, Gandhi, Sonia, Gamblin, Steve, Bauer, David L.V., Kassiotis, George, Howell, Michael, Nicholson, Emma, Walker, Susanna, Wilkinson, Robert J., Larkin, James, and Turajlic, Samra

Published
2022
Full Text
View/download PDF

43. Targeting TLR4 during vaccination boosts MAdCAM-1 + lymphoid stromal cell activation and promotes the aged germinal center response

Author

Denton, Alice E., primary, Dooley, James, additional, Cinti, Isabella, additional, Silva-Cayetano, Alyssa, additional, Fra-Bido, Sigrid, additional, Innocentin, Silvia, additional, Hill, Danika L., additional, Carr, Edward J., additional, McKenzie, Andrew N.J., additional, Liston, Adrian, additional, and Linterman, Michelle A., additional

Published
2022
Full Text
View/download PDF

44. The Impact of Vaccination on Incidence and Outcomes of SARS-CoV-2 Infection in Patients with Kidney Failure in Scotland

Author

Bell, Samira, primary, Campbell, Jacqueline, additional, Lambourg, Emilie, additional, Watters, Chrissie, additional, O’Neil, Martin, additional, Almond, Alison, additional, Buck, Katharine, additional, Carr, Edward J., additional, Clark, Laura, additional, Cousland, Zoe, additional, Findlay, Mark, additional, Joss, Nicola, additional, Metcalfe, Wendy, additional, Petrie, Michaela, additional, Spalding, Elaine, additional, Traynor, Jamie P., additional, Sanu, Vinod, additional, Thomson, Peter, additional, Methven, Shona, additional, and Mark, Patrick B., additional

Published
2022
Full Text
View/download PDF

45. Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: a nested case-control within the SIREN study (accepted)

Author

Atti, Ana, Insalata, Ferdinando, Carr, Edward J, Otter, Ashley D, Castillo-Olivares, Javier, Wu, Mary, Harvey, Ruth, Howell, Michael, Chan, Andrew, Lyall, Jonathan, Temperton, Nigel J., Cantoni, Diego, da Costa, Kelly, Nadesalingam, Angalee, Taylor-Kerr, Andrew, Hettiarachchi, Nipunadi, Tranquillini, Caio, Hewson, Jacqueline, Cole, Michelle J, Foulkes, Sarah, Munro, Katie, Monk, Edward J M, Milligan, Iain D, Linley, Ezra, Chand, Meera A, Brown, Colin S, Islam, Jasmin, Semper, Amanda, Charlett, Andre, Heeney, Jonathan L, Beale, Rupert, Zambon, Maria, Hopkins, Susan, Brooks, Tim, and Hall, Victoria

Abstract

Objectives: To investigate serological differences between SARS-CoV-2 reinfection cases and contemporary controls, to identify antibody correlates of protection against reinfection. Methods: We performed a case-control study, comparing reinfection cases with singly infected individuals pre-vaccination, matched by gender, age, region and timing of first infection. Serum samples were tested for anti-SARS-CoV-2 spike (anti-S), anti-SARS-CoV-2 nucleocapsid (anti-N), live virus microneutralisation (LV-N) and pseudovirus microneutralisation (PV-N). Results were analysed using fixed effect linear regression and fitted into conditional logistic regression models. Results: We identified 23 cases and 92 controls. First infections occurred before November 2020; reinfections occurred before February 2021, pre-vaccination. Anti-S levels, LV-N and PV-N titres were significantly lower among cases; no difference was found for anti-N levels. Increasing anti-S levels were associated with reduced risk of reinfection (OR 0•63, CI 0•47-0•85), but no association for anti-N levels (OR 0•88, CI 0•73-1•05). Titres >40 were correlated with protection against reinfection for LV-N Wuhan (OR 0•02, CI 0•001-0•31) and LV-N Alpha (OR 0•07, CI 0•009-0•62). For PV-N, titres >100 were associated with protection against Wuhan (OR 0•14, CI 0•03-0•64) and Alpha (0•06, CI 0•008-0•40). Conclusions: Before vaccination, protection against SARS-CoV-2 reinfection was directly correlated with anti-S levels, PV-N and LV-N titres, but not with anti-N levels. Detectable LV-N titres were sufficient for protection, whilst PV-N titres >100 were required for a protective effect., Author's Accepted Manuscript

Published
2022
Full Text
View/download PDF

46. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients

Author

Adenwalla, Sherna F, Bird, Paul, Holmes, Christopher, Hull, Katherine L, March, Daniel S, Selvaskandan, Haresh, Silva, Jorge J, Tang, Julian W, Hester, Joanna, Issa, Fadi, Barnardo, Martin, Friend, Peter J, Davenport, Andrew, Goodlad, Catriona, Gopalan, Vignesh, Tangwonglert, Theerasak, Stauss, Hans J, Richter, Alex G, Cunningham, Adam F, Perez-Toledo, Marisol, Banham, Gemma D, Wall, Nadya, Clarke, Candice L, Prendecki, Maria, Clayton, Bobbi, Namjou, Sina, Silva, Vanessa, Poulten, Meghan, Bawumia, Philip, Miah, Murad, Sade, Samuel, Miranda, Mauro, Taylor, Tom, D'Angelo, Ilenia, Cabrera Jarana, Mercedes, Rahman, Mahbubur, Abreu, Janet, Sandhar, Sandeep, Bailey, Neil, Caidan, Simon, Caulfield, Marie, Wu, Mary, Harvey, Ruth, Adams, Lorin, Kavanagh, Caitlin, Warchal, Scott, Sawyer, Chelsea, Gavrielides, Mike, Kandasamy, Jag, Ambrose, Karen, Strange, Amy, Abiola, Titilayo, O'Reilly, Nicola, Hobson, Philip, Agau-Doce, Ana, Russell, Emma, Riddell, Andrew, Kjaer, Svend, Borg, Annabel, Roustan, Chloë, Carr, Edward J, Wall, Emma C, Kelly, Gavin, Hussain, Saira, Howell, Michael, Kassiotis, George, Swanton, Charles, Gandhi, Sonia, Bauer, David LV, Billany, Roseanne E, Graham-Brown, Matthew PM, Beckett, Joseph, Bull, Katherine, Shankar, Sushma, Henderson, Scott, Motallebzadeh, Reza, Salama, Alan D, Harper, Lorraine, Mark, Patrick B, McAdoo, Stephen, Willicombe, Michelle, and Beale, Rupert

Published
2021
Full Text
View/download PDF

47. Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancer

Author

Fendler, Annika, primary, Shepherd, Scott T.C., additional, Au, Lewis, additional, Wilkinson, Katalin A., additional, Wu, Mary, additional, Schmitt, Andreas M., additional, Tippu, Zayd, additional, Farag, Sheima, additional, Rogiers, Aljosja, additional, Harvey, Ruth, additional, Carlyle, Eleanor, additional, Edmonds, Kim, additional, Rosario, Lyra Del, additional, Lingard, Karla, additional, Mangwende, Mary, additional, Holt, Lucy, additional, Ahmod, Hamid, additional, Korteweg, Justine, additional, Foley, Tara, additional, Barber, Taja, additional, Emslie-Henry, Andrea, additional, Caulfield-Lynch, Niamh, additional, Byrne, Fiona, additional, Shum, Benjamin, additional, Gerard, Camille L., additional, Deng, Daqi, additional, Kjaer, Svend, additional, Song, Ok-Ryul, additional, Queval, Christophe, additional, Kavanagh, Caitlin, additional, Wall, Emma C., additional, Carr, Edward J., additional, Namjou, Sina, additional, Caidan, Simon, additional, Gavrielidis, Mike, additional, McRae, James, additional, Kelly, Gavin, additional, Peat, Kema, additional, Kelly, Denise, additional, Murra, Aida, additional, Kelly, Kayleigh, additional, O'Flaherty, Molly, additional, Shea, Robyn L., additional, Gardner, Gail, additional, Murray, Darren, additional, Yousaf, Nadia, additional, Jhanji, Shaman, additional, As, Nicholas Van, additional, Young, Kate, additional, Furness, Andre J.S., additional, Pickering, Lisa, additional, Beale, Rupert, additional, Swanton, Charles, additional, Ghandi, Sonia, additional, Gamblin, Steve, additional, Bauer, David L.V., additional, Kassiotis, George, additional, Howell, Michael, additional, Nicholson, Emma, additional, Wilkinson, Robert J., additional, Larkin, James, additional, and Turajlic, Samra, additional

Published
2021
Full Text
View/download PDF

49. SARS-CoV-2 mucosal neutralising immunity after vaccination

Author

Carr, Edward J, Dowgier, Guilia, Greenwood, David, Herman, Lou S, Hobbs, Agnieszka, Ragno, Martina, Stevenson-Leggett, Phoebe, Gahir, Joshua, Townsley, Hermaleigh, Harvey, Ruth, Bailey, Chris, Fowler, Ashley S, Miah, Murad, Smith, Callie, Miranda, Mauro, Bawumia, Philip, Mears, Harriet V, Adams, Lorin, Hatipoglu, Emine, O'Reilly, Nicola, Warchal, Scott, Sawyer, Chelsea, Ambrose, Karen, Strange, Amy, Kelly, Gavin, Beale, Rupert, Papineni, Padmasayee, Corrah, Tumena, Gilson, Richard, Gamblin, Steve, Kassiotis, George, Libri, Vincenzo, Williams, Bryan, Swanton, Charles, Gandhi, Sonia, Bauer, David L V, Wall, Emma, and Wu, Mary Y

Published
2024
Full Text
View/download PDF

50. The impact of Omicron on outcomes following infection with SARS-CoV-2 in patients with kidney failure in Scotland.

Author

Bell, Samira, Campbell, Jacqueline, Watters, Chrissie, O'Neil, Martin, Almond, Alison, Buck, Katharine, Carr, Edward J, Cousland, Zoe, Findlay, Mark, Joss, Nicola, Metcalfe, Wendy, Spalding, Elaine, Methven, Shona, and Mark, Patrick B

Subjects
KIDNEY failure, SARS-CoV-2, SARS-CoV-2 Omicron variant
Abstract

Despite increasing transmissibility and dramatic rises in the number patients experiencing SARS-CoV-2 infection, outcomes have improved in those patients requiring KRT with SARS-CoV-2 infection. As of 27 March 2022, 4815 patients, which amounts to 90% of the prevalent KRT population in Scotland, had received at least three doses of a SARS-CoV-2 vaccine (88% of dialysis patients and 91% of transplant patients), and 46% a fourth dose. [Extracted from the article]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results